Cargando…
Validation of a small molecule inhibitor of PDE6D-RAS interaction with favorable anti-leukemic effects
RAS mutations prevalent in high-risk leukemia have been linked to relapse and chemotherapy resistance. Efforts to directly target RAS proteins have been largely unsuccessful. However, since RAS-mediated transformation is dependent on signaling through the RAS-related C3 botulinum toxin substrate (RA...
Autores principales: | Canovas Nunes, Sara, De Vita, Serena, Anighoro, Andrew, Autelitano, François, Beaumont, Edward, Klingbeil, Pamela, McGuinness, Meaghan, Duvert, Beatrice, Harris, Chad, Yang, Lu, Pokharel, Sheela Pangeni, Chen, Chun-Wei, Ermann, Monika, Williams, David A., Xu, Haiming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9010429/ https://www.ncbi.nlm.nih.gov/pubmed/35422065 http://dx.doi.org/10.1038/s41408-022-00663-z |
Ejemplares similares
-
Stabilization of
the RAS:PDE6D
Complex Is a Novel Strategy to Inhibit RAS Signaling
por: Yelland, Tamas, et al.
Publicado: (2022) -
Activation of PDE10 and PDE11
por: Jäger, Ronald, et al.
Publicado: (2011) -
PDE6D Inhibitors
with a New Design Principle Selectively
Block K-Ras Activity
por: Siddiqui, Farid A., et al.
Publicado: (2019) -
PDE4DIP contributes to colorectal cancer growth and chemoresistance through modulation of the NF1/RAS signaling axis
por: Pan, Rulu, et al.
Publicado: (2023) -
Computational Study on Selective PDE9 Inhibitors on PDE9-Mg/Mg, PDE9-Zn/Mg, and PDE9-Zn/Zn Systems
por: Sivakumar, Dakshinamurthy, et al.
Publicado: (2021)